Overview |
bs-11592R-FITC |
NAT8B Polyclonal Antibody, FITC Conjugated |
WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Mouse, Rat, Sheep, Pig, Horse |
Specifications |
FITC |
Rabbit |
KLH conjugated synthetic peptide derived from human NAT8B |
221-227/227 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
Cell membrane |
Camello like protein 2; Camello-like protein 2; CML2; Hcml2; N acetyltransferase 8B; NAT8B; NAT8B_HUMAN; NAT8BP; Probable N acetyltransferase 8B; Probable N-acetyltransferase 8B. |
Acetyltransferases and deacetylases are protein groups most often associated with oncogenesis and cell cycle regulation. NAT-8B (N-acetyltransferase 8B), also known as CML2 (camello-like protein 2), is a 227 amino acid single-pass membrane protein that is implicated in gastrulation regulation. A member of the camello family, NAT-8B contains one N-acetyltransferase domain and is encoded by a gene that maps to human chromosome 2p13.2. The NAT-8B gene is susceptible to a nonsense mutation at Serine 16, which leads to a stop codon and subsequently, a non-functional protein that is truncated in length. Similarly, a nonsense mutation at Glutamine 168 is thought to lead to a non-functional protein, as it causes the N-acetyltransferase to become disrupted. Human chromosome 2 consists of 237 million bases, encodes over 1,400 genes and makes up approximately 8% of the human genome. A number of genetic diseases are linked to genes on chromosome 2 including Harlequin icthyosis, sitosterolemia and Alstr syndrome. |
Application Dilution |
WB |
1:300-5000 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |